Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase NA 11Phase 3 5Phase 1/2 5Phase 1 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 5Terminated 4Withdrawn 3Active not recruiting 3Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

venetoclax 1tetrathiomolybdate 1tagraxofusp 1pembrolizumab 1blinatumomab 1Injections 1Cyclophosphamide 1Capecitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Neoplasm, Residual × Clear all
NCT04521231 2026-05-01

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Recruiting
281 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
31 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT04707300 2025-11-20

HTLP-ONCO

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Recruiting
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT01898039 2025-10-02

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Hadassah Medical Organization

Phase 1/2 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡